Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects.

To investigate the efficacy of endocrine parathyroid hormone treatment on tissue-engineered bone regeneration, massive femoral defects in C57Bl/6 mice were reconstructed with either 100:0 or 85:15 poly-lactic acid (PLA)/beta-tricalcium phosphate (β-TCP) scaffolds (hereafter PLA or PLA/βTCP, respectively), which were fabricated with low porosity (<30%) to improve their structural rigidity. Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline. Bone regeneration was assessed longitudinally using planar X-ray and quantitative microcomputed tomography, and the reconstructed femurs were evaluated at 9 weeks either histologically or biomechanically to determine their torsional strength and rigidity. Teriparatide treatment increased bone volume and bone mineral content significantly at 6 weeks and led to enhanced trabeculated bone callus formation that appeared to surround and integrate with the scaffold, thereby establishing union by bridging bone regeneration across the segmental defect in 30% of the reconstructed femurs, regardless of the scaffold type. However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds. Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union. Taken together, these observations suggest that intermittent, systemic parathyroid hormone treatment can enhance bone regeneration in scaffold-reconstructed femoral defects, which can be further enhanced by mineralized (βTCP) particles within the scaffold.

[1]  E. Schwarz,et al.  Evaluation of dense polylactic acid/beta-tricalcium phosphate scaffolds for bone tissue engineering. , 2010, Journal of biomedical materials research. Part A.

[2]  H. Zreiqat,et al.  Beta-tricalcium phosphate exerts osteoconductivity through alpha2beta1 integrin and down-stream MAPK/ERK signaling pathway. , 2010, Biochemical and biophysical research communications.

[3]  Paul Childress,et al.  Nmp4/CIZ: road block at the intersection of PTH and load. , 2010, Bone.

[4]  Qixin Zheng,et al.  Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[5]  S. Jatana,et al.  Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). , 2008, The spine journal : official journal of the North American Spine Society.

[6]  E. Schwarz,et al.  Teriparatide (1‐34 human PTH) regulation of osterix during fracture repair , 2008, Journal of cellular biochemistry.

[7]  R. Brower,et al.  A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L 4 – L 5 , 2009 .

[8]  James D. Kang,et al.  Safety Assessment of Intradiscal Gene Therapy II: Effect of Dosing and Vector Choice , 2008, Spine.

[9]  S. Goldstein,et al.  Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. , 2008, Bone.

[10]  R. T. Allen,et al.  Bone Morphogenetic Protein-2 (BMP-2) in the Treatment of Pyogenic Vertebral Osteomyelitis , 2007, Spine.

[11]  S. Kakar,et al.  Enhanced Chondrogenesis and Wnt Signaling in PTH‐Treated Fractures , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Andrea Giustina,et al.  Mechanisms of anabolic therapies for osteoporosis. , 2007, The New England journal of medicine.

[13]  A. Vaccaro,et al.  Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion , 2007, International Orthopaedics.

[14]  Tetsuji Yamamoto,et al.  Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. , 2007, Bone.

[15]  N. Anand,et al.  Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. , 2007, The spine journal : official journal of the North American Spine Society.

[16]  R. Bittar,et al.  BMP-7 (OP-1®) Safety in anterior cervical fusion surgery , 2006, Journal of Clinical Neuroscience.

[17]  J. Foley,et al.  Parathyroid hormone hormone-related protein and the PTH receptor regulate angiogenesis of the skin. , 2006, The Journal of investigative dermatology.

[18]  C. Laurencin,et al.  Bone tissue engineering by gene delivery. , 2006, Advanced drug delivery reviews.

[19]  Yoshihisa Suzuki,et al.  Repair of 20-mm long rabbit radial bone defects using BMP-derived peptide combined with an alpha-tricalcium phosphate scaffold. , 2006, Journal of biomedical materials research. Part A.

[20]  M. Holick PTH (1–34): A Novel Anabolic Drug for the Treatment of Osteoporosis , 2005, Southern medical journal.

[21]  T. Einhorn,et al.  Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. , 2005, Bone.

[22]  R. Jilka,et al.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.

[23]  S. Goldstein,et al.  Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. , 2005, Bone.

[24]  B. Mitlak,et al.  Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). , 2005, The Journal of bone and joint surgery. American volume.

[25]  S. Komatsubara,et al.  Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. , 2005, Bone.

[26]  E. Schwarz,et al.  A novel murine segmental femoral graft model , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[27]  Kevin D Bunting,et al.  Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. , 2004, Current gene therapy.

[28]  M. Karperien,et al.  Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist , 2004, The Journal of experimental medicine.

[29]  J. F. Whitfield,et al.  Treatment with Parathyroid Hormone hPTH(1-34), hPTH(1-31), and Monocyclic hPTH(1-31) Enhances Fracture Strength and Callus Amount After Withdrawal Fracture Strength and Callus Mechanical Quality Continue to Increase , 2004, Calcified Tissue International.

[30]  X. Guo,et al.  Trabecular Bone Response to Mechanical and Parathyroid Hormone Stimulation: The Role of Mechanical Microenvironment , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  S. Goldstein,et al.  Combination of Local and Systemic Parathyroid Hormone Enhances Bone Regeneration , 2003, Clinical orthopaedics and related research.

[32]  Z. Xiong,et al.  Development of a porous poly(L-lactic acid)/hydroxyapatite/collagen scaffold as a BMP delivery system and its use in healing canine segmental bone defect. , 2003, Journal of biomedical materials research. Part A.

[33]  C. Deal,et al.  Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis. , 2003, Cleveland Clinic journal of medicine.

[34]  T. Einhorn,et al.  Mechanisms for the Enhancement of Fracture Healing in Rats Treated With Intermittent Low‐Dose Human Parathyroid Hormone (1–34) , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  C. Rimnac,et al.  Fracture resistance of gamma radiation sterilized cortical bone allografts , 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[36]  P. Aspenberg,et al.  Implant fixation enhanced by intermittent treatment with parathyroid hormone. , 2001, The Journal of bone and joint surgery. British volume.

[37]  D. Hutmacher,et al.  Scaffolds in tissue engineering bone and cartilage. , 2000, Biomaterials.

[38]  A. Lalwani,et al.  Safety of adeno-associated virus as cochlear gene transfer vector: analysis of distant spread beyond injected cochleae. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  P. Esbrit,et al.  C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. , 2000, Journal of the American Society of Nephrology : JASN.

[40]  Jeffrey Bonadio,et al.  Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration , 1999, Nature Medicine.

[41]  H. Oxlund,et al.  Intermittent Parathyroid Hormone (1–34) Treatment Increases Callus Formation and Mechanical Strength of Healing Rat Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  J. Reeve PTH: A future role in the management of osteoporosis? , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  P. Scherer,et al.  Accelerated fracture healing. , 1976, Journal of the American Podiatry Association.

[44]  Chi-Hwa Wang,et al.  Three‐dimensional fibrous PLGA/HAp composite scaffold for BMP‐2 delivery , 2008, Biotechnology and bioengineering.

[45]  Amy L Lerner,et al.  Micro-computed tomography prediction of biomechanical strength in murine structural bone grafts. , 2007, Journal of biomechanics.

[46]  Marcel Karperien,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation , 2022 .